Log in

NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, Forecast & News

$0.37
-0.01 (-2.64 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$0.36
Now: $0.37
$0.38
50-Day Range
$0.33
MA: $0.35
$0.38
52-Week Range
$0.25
Now: $0.37
$3.08
Volume494,196 shs
Average Volume837,578 shs
Market Capitalization$12.24 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNAT
CUSIPN/A
Phone858-376-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.59 million
Book Value$0.91 per share

Profitability

Net Income$-18,010,000.00

Miscellaneous

Employees30
Market Cap$12.24 million
Next Earnings Date3/13/2020 (Estimated)
OptionableOptionable

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.


Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The biotechnology company earned $3.38 million during the quarter, compared to the consensus estimate of $6.50 million. Conatus Pharmaceuticals had a negative net margin of 43.92% and a negative return on equity of 51.74%. View Conatus Pharmaceuticals' Earnings History.

When is Conatus Pharmaceuticals' next earnings date?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Conatus Pharmaceuticals.

What price target have analysts set for CNAT?

3 brokers have issued 12-month price objectives for Conatus Pharmaceuticals' shares. Their forecasts range from $1.50 to $1.70. On average, they expect Conatus Pharmaceuticals' stock price to reach $1.60 in the next twelve months. This suggests a possible upside of 333.6% from the stock's current price. View Analyst Price Targets for Conatus Pharmaceuticals.

What is the consensus analysts' recommendation for Conatus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Conatus Pharmaceuticals.

What are Wall Street analysts saying about Conatus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California. " (10/29/2019)
  • 2. HC Wainwright analysts commented, "We project OpEx to decline further in 2019 as clinical trial expenditures for emricasan continue to taper down after the ENCORE-LF trial’s top-line data readout. Conatus ended 1Q19 with $33.8M in cash and cash equivalents, and guides to a year-end cash balance of $10-15M, excluding any potential milestone payments from Novartis." (5/3/2019)

Has Conatus Pharmaceuticals been receiving favorable news coverage?

Headlines about CNAT stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Conatus Pharmaceuticals earned a news impact score of 0.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Conatus Pharmaceuticals.

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,090,000 shares, a decrease of 33.9% from the October 31st total of 1,650,000 shares. Based on an average daily trading volume, of 671,700 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.4% of the company's stock are sold short. View Conatus Pharmaceuticals' Current Options Chain.

Who are some of Conatus Pharmaceuticals' key competitors?

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), Cascadian Therapeutics (CASC), Antares Pharma (ATRS), Dextera Surgical (DXTR), Vaxart (VXRT), Novavax (NVAX), Exelixis (EXEL) and Verastem (VSTM).

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:
  • Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
  • Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
  • Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
  • Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications

How do I buy shares of Conatus Pharmaceuticals?

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $0.37.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $12.24 million and generates $33.59 million in revenue each year. The biotechnology company earns $-18,010,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Conatus Pharmaceuticals employs 30 workers across the globe.View Additional Information About Conatus Pharmaceuticals.

What is Conatus Pharmaceuticals' official website?

The official website for Conatus Pharmaceuticals is http://www.conatuspharma.com/.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]


MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  492 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  749
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel